ABSTRACT Forty-six patients with histologically confirmed lung cancer received treatment with the cytotoxic drug 
VP-16-213 (4'-demethylepipodophyllotoxin 9-(4, 6-O-ethylidene-B-D-glucopyranoside) is a semisynthetic podophyllin derivative reported to show activity in small cell carcinoma of the bronchus.1 2 We report a study of the activity of oral in a variety of cell types of bronchogenic cancer.
Patients and methods
Forty-six patients with advanced histologically confirmed lung cancer were studied. Cell types were squamous carcinoma (19 cases), small cell carcinoma (10 cases), adenocarcinoma (six cases), undifferentiated carcinoma (11 cases). The term undifferentiated carcinoma was used when precise classification was not possible. in all cell types of lung cancer. The group studied had very widespread disease and the overall response rate is probably best judged as 11 of the 33 patients surviving to receive cycle 2. In addition to its effect in small cell carcinomas VP-16-213 is also effective in the other cell types against which its effect has not previously been tested. An impressive feature was the low level of haematological toxicity, especially considering that 14 patients had previously received radiotherapy or other forms of chemotherapy. We may have underestimated the incidence of leucopenia and thrombocytopenia by measuring blood counts before the next cycle (28 days) rather than at the nadir (10-14 days) but this seems justified as it is the count before the next cycle which determines whether to proceed with chemotherapy. Certainly, there was no evidence of progressive marrow depression. The gastrointestinal toxicity was mild and this form of chemotherapy was acceptable to patients.
Addendum
The demonstration that oral VP-16-213 showed effectiveness and low toxicity led to three subsequent pilot studies, all of which were abandoned because of unexplained marrow toxicity. Schedule A consisted of oral VP-16-213, 200 mg orally days 1 to 5, vincristine 2 mg iv, on day 1 and methotrexate 300 mg iv on day 1, followed 24 hours later by oral leucovorin 15 mg six hourly for six doses. Schedule B used the same doses of VP-16-213 and vincristine but only 100 mg of methotrexate iv on day 1 and folinic acid rescue was extended to 10 mg orally six hourly for nine doses starting at 24 hours. Schedule 
